Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series
Citations Over TimeTop 10% of 2021 papers
Abstract
Dupilumab is a relatively new treatment option for patients with moderate to severe atopic dermatitis. There is a lack of knowledge about the effects of treatment with dupilumab during conception for both men and women, as well as during pregnancy and lactation in women. We report four patients (two men, two women) who expressed a wish to conceive during treatment with dupilumab in daily practice. Both men conceived during dupilumab treatment, while the two women discontinued dupilumab because of anticipated pregnancy. Apart from disease flares in both of the patients who discontinued treatment, no complications were reported concerning the ability to conceive, the course of the pregnancy or the fetal outcome. We present an overview of the current available literature on dupilumab during conception, pregnancy and lactation, which can guide considerations for patients on dupilumab wishing to conceive a child. Until more data are available, preference should be given to treatment with topical corticosteroids, phototherapy, systemic corticosteroids and ciclosporin.
Related Papers
- Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.(2016)
- → Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial(2018)4 cited
- → Case report of the dupilumab applying in atopic dermatitis child(2021)1 cited
- → The Use of Dupilumab in Severe Atopic Dermatitis During Pregnancy: A Case Report(2021)1 cited
- → A Systemic Review of Dupilumab Efficacy and Safety by Phenotypic Variations of Atopic Dermatitis(2021)